AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Jan 21, 2021
31637_dirs_2021-01-20_4c627740-4bc9-472d-aebe-8326ea7450cb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-01-15
Reporting Person: Krognes Steve E. (CFO and Treasurer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-15 | Common Stock | S | 14801 | $70.099 | Disposed | 985199 | Indirect |
| 2021-01-15 | Common Stock | S | 12981 | $70.962 | Disposed | 972218 | Indirect |
| 2021-01-15 | Common Stock | S | 8071 | $71.992 | Disposed | 964147 | Indirect |
| 2021-01-15 | Common Stock | S | 14147 | $73.006 | Disposed | 950000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 10177 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.445 to $70.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.47 to $71.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.56 to $72.555 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $72.565 to $73.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.